Exendin-4 (Ex4) is a potent and long-lasting agonist of glucagon-like peptide-1 (GLP-1), which has been previously found to stimulate pituitary-adrenal axis in the rat. Aim of the present study was to gain insight into the mechanism(s) involved in the Ex4-induced rise in the rat plasma concentrations of ACTH, aldosterone and corticosterone. Preliminary time- and dose-response studies showed that the maximum stimulating effect of Ex4 occurred within 1 or 2 h and at dose ranging from 0.5 to 2.0 nmol/100 g body weight. The GLP-1 receptor (GLP-1R) antagonist Ex(9-39) did not significantly affect ACTH, aldosterone and cortico-sterone responses to Ex4. Neither the administration of CRH and arginine vasopressin (AVP)-receptor antagonists nor adren...
The hypothalamo-pituitary-adrenal axis is controlled by complex regulatory mechanisms. Numerous fact...
Exendin-(9,39) is a competitive antagonist of Glucagon-Like Peptide-1 (GLP-1) at its receptor. Howev...
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of...
Exendin-4 (Ex4) is a potent and long-lasting agonist of glucagon-like peptide-1 (GLP-1), which has b...
Summary: Agonists for glucagon-like-peptide-1 receptor (GLP-1R) are currently used for the treatment...
Objective Glucagon-like peptide-1 (GLP-1) analogs are attractive options for the treatment of type ...
The effects of glucagon and glucagon-like peptide-1 (GLP-1) on the secretory activity of rat adrenoc...
The acute effect of endothelin-1 (ET-1) on the hypothalamo-pituitary-adrenal (HPA) axis has been inv...
Objective: Corticotrophin (ACTH)-induced hypertension in the rat is prevented by L- but not D-argini...
Systemic injection of the mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.), increased plasma co...
Neuropeptides (NP) B and W are hypothalamic peptides involved in the regulation of feeding and neuro...
Copyright © 2013 A. Harkavyi et al. This is an open access article distributed under the Creative Co...
Parkinson's disease (PD) is a progressive neurodegenerative disorder with no current cure and therap...
Glucagon-like peptide-1 (GLP-1) stimulates glucose-de-pendent insulin secretion and inhibits food in...
1. This study exploited established immunoneutralization protocols and an N-terminal annexin 1 pepti...
The hypothalamo-pituitary-adrenal axis is controlled by complex regulatory mechanisms. Numerous fact...
Exendin-(9,39) is a competitive antagonist of Glucagon-Like Peptide-1 (GLP-1) at its receptor. Howev...
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of...
Exendin-4 (Ex4) is a potent and long-lasting agonist of glucagon-like peptide-1 (GLP-1), which has b...
Summary: Agonists for glucagon-like-peptide-1 receptor (GLP-1R) are currently used for the treatment...
Objective Glucagon-like peptide-1 (GLP-1) analogs are attractive options for the treatment of type ...
The effects of glucagon and glucagon-like peptide-1 (GLP-1) on the secretory activity of rat adrenoc...
The acute effect of endothelin-1 (ET-1) on the hypothalamo-pituitary-adrenal (HPA) axis has been inv...
Objective: Corticotrophin (ACTH)-induced hypertension in the rat is prevented by L- but not D-argini...
Systemic injection of the mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.), increased plasma co...
Neuropeptides (NP) B and W are hypothalamic peptides involved in the regulation of feeding and neuro...
Copyright © 2013 A. Harkavyi et al. This is an open access article distributed under the Creative Co...
Parkinson's disease (PD) is a progressive neurodegenerative disorder with no current cure and therap...
Glucagon-like peptide-1 (GLP-1) stimulates glucose-de-pendent insulin secretion and inhibits food in...
1. This study exploited established immunoneutralization protocols and an N-terminal annexin 1 pepti...
The hypothalamo-pituitary-adrenal axis is controlled by complex regulatory mechanisms. Numerous fact...
Exendin-(9,39) is a competitive antagonist of Glucagon-Like Peptide-1 (GLP-1) at its receptor. Howev...
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of...